HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
EN
CN
HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Blood Diseases Volume" for the treatment of Chinese patent medicines for blood diseases
2018-11-22
PREV
Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine
NEXT
Shengbai Oral Liquid: Progress and Prospect of Integrated Traditional Chinese and Western Medicine in Clinical Oncology
Hot news
How much do you know about leukopen...
Meta-analysis of the efficacy of S...
Efficacy of Shengbai mixture on bo...
A complete TCM treatment for leu...
Should leukopenia be discontinued i...
Polysaccharides were included in th...
Should I stop chemotherapy if I h...
What kind of treatment is needed fo...